drugset / Trial / NCT01997840
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma. Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma
Timeline
- Start
- 2014-03-01
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ricolinostat | Small molecule | 160 mg | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |
| Background | Pomalidomide | Other / unclassified | 4 mg | — |